---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-118573"
form_type: "8-K"
ticker: "ZBH"
cik: "0001136869"
company_name: "ZIMMER BIOMET HOLDINGS, INC."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:00:56.849738+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zimmer Biomet Q3 sales up 4.1% cc; lowers FY2024 guidance

## Summary
- Q3 net sales $1.824B (+4.1% cc); diluted EPS $1.23, adjusted EPS $1.74.
- FY2024 constant currency revenue growth guidance narrowed to 4.25%-4.75% from 5.0%-6.0%.
- FY2024 adjusted diluted EPS guidance lowered to $7.95-$8.05 from $8.00-$8.15.
- CEO Ivan Tornos cited ERP implementation challenges as headwind to full-year performance.
- Completed acquisition of OrthoGrid Systems (AI hip guidance); launched Z1 Femoral Hip System.

## SEC filing metadata
- accession: 0000950170-24-118573
- form_type: 8-K
- ticker: ZBH
- cik: 0001136869
- company_name: ZIMMER BIOMET HOLDINGS, INC.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1136869/000095017024118573/0000950170-24-118573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1136869/000095017024118573/zbh-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-118573
- JSON: https://secwatch.observer/filing/0000950170-24-118573.json
- Plain text: https://secwatch.observer/filing/0000950170-24-118573.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.